| Literature DB >> 26637846 |
Laura A Sordillo1, Peter P Sordillo1, Lawrence Helson2.
Abstract
Glioblastoma multiforme is a highly aggressive primary cancer of the brain associated with a poor prognosis. Modest increases in survival can sometimes be achieved with the use of temozolomide and radiation therapy after surgery, but second-line therapy after recurrence has a limited efficacy. Curcumin has demonstrated promising results against this form of cancer in experimental models. The reported activity of curcumin against cancer stem cells, a major cause of glioblastoma resistance to therapy, and its ability to augment the apoptotic effects of ceramides, suggest it would have a synergistic effect with cytotoxic chemotherapy agents currently used in second-line therapy, such as lomustine. CopyrightEntities:
Keywords: Glioblastoma; blood–brain barrier; cancer stem cells; ceramide; combination chemotherapy; curcumin; lipophilic agent; lomustine; review
Mesh:
Substances:
Year: 2015 PMID: 26637846
Source DB: PubMed Journal: Anticancer Res ISSN: 0250-7005 Impact factor: 2.480